HUP9600266A3 - Pharmaceutical organic salt solutions for endonasal application - Google Patents

Pharmaceutical organic salt solutions for endonasal application

Info

Publication number
HUP9600266A3
HUP9600266A3 HU9600266A HUP9600266A HUP9600266A3 HU P9600266 A3 HUP9600266 A3 HU P9600266A3 HU 9600266 A HU9600266 A HU 9600266A HU P9600266 A HUP9600266 A HU P9600266A HU P9600266 A3 HUP9600266 A3 HU P9600266A3
Authority
HU
Hungary
Prior art keywords
salt solutions
organic salt
pharmaceutical organic
endonasal application
endonasal
Prior art date
Application number
HU9600266A
Other languages
English (en)
Original Assignee
Therapicon Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapicon Srl filed Critical Therapicon Srl
Publication of HU9600266D0 publication Critical patent/HU9600266D0/hu
Publication of HUP9600266A2 publication Critical patent/HUP9600266A2/hu
Publication of HUP9600266A3 publication Critical patent/HUP9600266A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU9600266A 1995-02-08 1996-02-07 Pharmaceutical organic salt solutions for endonasal application HUP9600266A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95101681A EP0726075A1 (en) 1995-02-08 1995-02-08 Pharmaceutical non-inorganic saline solutions for endonasal administration

Publications (3)

Publication Number Publication Date
HU9600266D0 HU9600266D0 (en) 1996-04-29
HUP9600266A2 HUP9600266A2 (en) 1997-06-30
HUP9600266A3 true HUP9600266A3 (en) 2000-09-28

Family

ID=8218965

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9600266A HUP9600266A3 (en) 1995-02-08 1996-02-07 Pharmaceutical organic salt solutions for endonasal application

Country Status (17)

Country Link
US (2) US6107277A (hu)
EP (3) EP0726075A1 (hu)
JP (2) JPH11506416A (hu)
KR (2) KR100430101B1 (hu)
AT (2) ATE191719T1 (hu)
AU (2) AU4787996A (hu)
BR (1) BR9607410A (hu)
CA (2) CA2210664A1 (hu)
DE (4) DE726075T1 (hu)
ES (2) ES2146869T3 (hu)
GB (1) GB9523442D0 (hu)
HU (1) HUP9600266A3 (hu)
PE (1) PE28397A1 (hu)
PL (1) PL183398B1 (hu)
PT (2) PT809654E (hu)
WO (2) WO1996024618A1 (hu)
ZA (2) ZA96779B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726075A1 (en) * 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
US6034064A (en) * 1995-04-07 2000-03-07 Hoechst Pharmaceuticals & Chemicals K.K. Peptides and therapeutic agent for autoimmune diseases containing the same
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
IT1298780B1 (it) * 1998-03-24 2000-02-02 Therapicon Srl Preparazioni parenterali a base di calcitonina
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AU783952B2 (en) * 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
WO2003002139A1 (fr) * 2001-06-29 2003-01-09 Asahi Kasei Kabushiki Kaisha Procede permettant d'ameliorer la stabilite de la preparation de proteines
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CN101237890A (zh) * 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
CN100349611C (zh) * 2005-11-25 2007-11-21 中国药科大学 鲑降钙素吸入粉雾剂及其制备方法
WO2010085700A2 (en) 2009-01-22 2010-07-29 Unigene Laboratories Inc. Treatment for obesity
CN103998052B (zh) 2011-11-02 2016-08-17 关键生物科学有限公司 用于治疗疾病和紊乱的肽类似物
US9533022B2 (en) 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926938A (en) * 1974-08-12 1975-12-16 Armour Pharma Synthesis of salmon calcitonin
US4217268A (en) * 1978-07-20 1980-08-12 Hughes John L Synthesis of peptides
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4659804A (en) * 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US4622386A (en) * 1985-03-28 1986-11-11 Armour Pharmaceutical Company [1,7-di-alanine]calcitonin
US4639510A (en) * 1985-10-04 1987-01-27 Armour Pharmaceutical Company (1-S-acetamidomethyl cysteine, 7-alanine)calcitonin
HUT44794A (en) * 1985-12-04 1988-04-28 Sandoz Ag Process for production of calcitonine-derivatives and medical preparatives containing such compounds
EP0298474B1 (en) * 1987-07-08 1992-11-19 Mitsubishi Petrochemical Co., Ltd. Novel calcitonin derivative and salt thereof
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3887494T2 (de) * 1987-11-13 1994-05-19 Smithkline Beecham Farma Ein Calcitonin sowie ein Glycyrrhizinat als Absorptionsförderer enthaltende Arzneimittel.
AU629552B2 (en) * 1988-06-16 1992-10-08 Teijin Limited S-sulfonated calcitonin derivatives
JPH0694851B2 (ja) * 1988-06-27 1994-11-24 株式会社日立製作所 蒸発燃料制御装置
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
JPH0643339B2 (ja) * 1990-05-25 1994-06-08 旭化成工業株式会社 カルシトニン類水溶液組成物の安定化法
IT1248725B (it) * 1990-06-12 1995-01-26 Sclavo Spa Composizione farmaceutica in polvere per somministrazione per via nasale contenente essenzialmente calcitonina ed un eccipiente idrosolubile
JPH078806B2 (ja) * 1990-08-16 1995-02-01 旭化成工業株式会社 カルシトニン類含有経鼻投与用乳剤
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
IT1244500B (it) * 1991-03-21 1994-07-15 Pulitzer Italiana Impiego di sali minerali di trometamina in composizioni farmaceutiche a base di calcitonina somministrabili per via rettale in terapia umana
IT1251685B (it) * 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
EP0726075A1 (en) * 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration

Also Published As

Publication number Publication date
ES2146869T3 (es) 2000-08-16
BR9607410A (pt) 1998-07-07
DE69620393D1 (de) 2002-05-08
KR100430101B1 (ko) 2006-02-13
ATE215381T1 (de) 2002-04-15
AU4787996A (en) 1996-08-27
DE69607749D1 (de) 2000-05-18
JPH11506416A (ja) 1999-06-08
US6107277A (en) 2000-08-22
JP4123309B2 (ja) 2008-07-23
PT809654E (pt) 2000-10-31
GB9523442D0 (en) 1996-01-17
HUP9600266A2 (en) 1997-06-30
WO1996024618A1 (en) 1996-08-15
ES2173267T3 (es) 2002-10-16
EP0809654B1 (en) 2000-04-12
PE28397A1 (es) 1997-08-22
KR100397034B1 (ko) 2003-11-13
ZA96835B (en) 1996-08-19
EP0726075A1 (en) 1996-08-14
PT809512E (pt) 2002-09-30
DE726075T1 (de) 1996-12-12
PL183398B1 (pl) 2002-06-28
EP0809512B1 (en) 2002-04-03
DE29622959U1 (de) 1998-03-05
DE69607749T2 (de) 2000-07-27
EP0809512A1 (en) 1997-12-03
ATE191719T1 (de) 2000-04-15
PL312683A1 (en) 1996-08-19
WO1996024370A1 (en) 1996-08-15
ZA96779B (en) 1996-08-29
KR19980702091A (ko) 1998-07-15
CA2212520A1 (en) 1996-08-15
CA2210664A1 (en) 1996-08-15
KR960030948A (ko) 1996-09-17
JPH08245417A (ja) 1996-09-24
AU4786396A (en) 1996-08-27
HU9600266D0 (en) 1996-04-29
US6087338A (en) 2000-07-11
DE69620393T2 (de) 2003-01-16
EP0809654A1 (en) 1997-12-03

Similar Documents

Publication Publication Date Title
HUP9600266A3 (en) Pharmaceutical organic salt solutions for endonasal application
GR3031304T3 (en) 6-Dimethylaminomethyl-1-phenyl-cyclo-hexane compounds as pharmaceutical agents
GR3032486T3 (en) 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol derivatives as pharmaceutical agents
EP0850057A4 (en) PHARMACEUTICAL COMPOSITIONS
GB9508823D0 (en) Drug Derivatives
HU9603498D0 (en) Pharmaceutical compounds
GB9515060D0 (en) Therapeutic heterocyclic compounds
GB9511166D0 (en) Pharmaceutical compounds
GB9517867D0 (en) Pharmaceutical compounds
GB9517866D0 (en) Pharmaceutical compounds
GB9517865D0 (en) Pharmaceutical compounds
GB9526437D0 (en) Pharmaceutical compounds
GB9522132D0 (en) Pharmaceutical compounds
GB9506273D0 (en) Pharmaceutical compounds
GB9502811D0 (en) Pharmaceutical compounds
GB9526439D0 (en) Pharmaceutical compound
PL307197A1 (en) Pharmaceutical agent
GB9515305D0 (en) Therapeutic heterocyclic compounds
GB9521463D0 (en) Therapeutic heterocyclic compounds
GB9509419D0 (en) Therapeutic heterocyclic compounds
GB9500924D0 (en) Organic compounds
GB9501035D0 (en) Organic compounds
GB9501038D0 (en) Organic compounds
GB9501155D0 (en) Organic compounds
GB9503092D0 (en) Organic compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees